Expression of monocyte chemoattractant protein-1 in Kawasaki disease: the anti-inflammatory effect of gamma globulin therapy.
We investigated the expression of monocyte chemoattractant protein-1 (MCP-1) mRNA, protein, and its bioactivity in plasma, mononuclear cells (MNC) and polymorphonuclear leukocytes (PML) in patients with Kawasaki disease, including those who were treated with intravenous gamma globulin. MCP-1 mRNA expression was increased in the MNC and the plasma level of MCP-1 and monocyte chemotactic activity in plasma in the acute phase as compared with healthy control levels and decreased after the gamma globulin therapy. The infused gamma globulin contained MCP-1 protein with monocyte chemotactic activity and did not show a neutralising effect against MCP-1 protein in vitro. Our results suggest that the infusion of gamma globulin may reduce the production of MCP-1 in MNC in patients with Kawasaki disease, subsequently reducing its level in plasma. The changes in MCP-1 level after gamma globulin therapy may serve to alleviate the symptoms in the acute phase in patients with Kawasaki disease.
Asano
T
T
Department of Pediatrics, Nippon Medical School, Tokyo 113-8603, Japan.
Ogawa
S
S
D000208:Acute Disease; D016022:Case-Control Studies; D018932:Chemokine CCL2 / Q000097:blood* / Q000235:genetics*; D002634:Chemotaxis, Leukocyte; D002675:Child, Preschool; D005260:Female; D015870:Gene Expression; D006801:Humans; D066298:In Vitro Techniques; D007223:Infant; D007262:Infusions, Intravenous; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D009504:Neutrophils / Q000276:immunology; D012333:RNA, Messenger / Q000097:blood / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D005719:gamma-Globulins / Q000008:administration & dosage / Q000627:therapeutic use*
D018932:Chemokine CCL2; D012333:RNA, Messenger; D005719:gamma-Globulins